Obese Patients on Warfarin at Double Risk of Major Bleeds

Obese patients had an 84% higher risk of a major bleeding event, compared to those of normal weight.
Obese patients had an 84% higher risk of a major bleeding event, compared to those of normal weight.

(HealthDay News) -- Obese patients taking warfarin have a higher risk of experiencing a bleeding event compared to their normal-weight counterparts, a new study suggests. The findings were presented at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology/Peripheral Vascular Disease 2015 Scientific Sessions, held in San Francisco.

Adedotun Ogunsua, M.D., and colleagues from the University of Massachusetts Medical School in Worcester followed 863 people taking warfarin for a year. The average age of those in the study was 69.5 years. Of all the study participants, 21% were considered at normal weight. 38% were classified as overweight and 41% were considered obese.

The researchers found that 71 people -- 8.2% -- experienced a bleeding event. About a third of these episodes were major (gastrointestinal, intracerebral, and retroperitoneal hemorrhage), and two-thirds were minor (epistaxis, hematuria, vaginal, and skin bleeds). 

When they looked at the data based on weight, the researchers found that people who were obese had an 84% higher risk of a major bleeding event. And, the heavier someone was, the greater their risk of bleeding while taking warfarin.

"Bleeding risk is higher in obese compared to normal-weight individuals who are on warfarin. Risk is higher with increasing body mass index," the authors write. "Future studies are needed to understand the mechanism by which obesity increases bleeding risk for patients on warfarin and whether similar risk [exists] for the novel oral anticoagulants."

Source

  1. American Heart Association News Release, May 8, 2015
Loading links....
You must be a registered member of Renal and Urology News to post a comment.